Feb. 2, 2022– More than a dozen pharmaceutical companies have pulled back on 340B drug pricing program discounts that federal law requires them to offer safety-net hospitals that care for the nation’s patients who are in the most need. New survey data demonstrate how these drugmaker actions already have taken major bites out of the resources that hospitals rely on to fulfill … [Read more...]
More Court Battles Ahead for 340B in 2022
Jan. 12, 2022– The dispute between safety-net hospitals and a growing group of drug companies over community-based pharmacies in the 340B drug pricing program is heading into a new phase of legal wrangling that ensures this fight will remain a dominant issue in the 340B world for months to come. As 2021 ended, two industry giants – Amgen and AbbVie – joined the group of … [Read more...]
A Hospital Community United Against Threats to 340B
Dec. 20, 2021— Hundreds of safety-net hospitals are urging the federal government to escalate its efforts to stop a group of drug companies that are refusing to offer drug discounts that the federal 340B drug pricing program requires. Today, more than 800 hospitals participating in 340B sent a letter to Health and Human Services (HHS) Secretary Xavier Becerra calling on the … [Read more...]
Eli Lilly Again Reports Big Revenue Gains From 340B Denials
Nov. 1, 2021– The first drug company to deny 340B drug pricing program discounts to safety-net hospitals, health centers, and clinics saw its U.S. revenues jump 26% in the third quarter of 2021, thanks in part to the higher prices it is charging for diabetes drugs sold to 340B providers. In a public financial report, Eli Lilly said its third-quarter U.S. revenue totaled … [Read more...]
Seventh Drug Company Told It is Violating 340B Law
Oct. 12, 2021– Eight drug companies have restricted access to discounts to safety-net providers through the 340B drug pricing program on drugs dispensed at community-based pharmacies. Now the government officially has informed all but one of those companies that they are in violation of federal law and must restore the discounted pricing. The most recent recipient of a … [Read more...]
HHS Takes Vital Next Step Toward Ending 340B Pricing Denials
Oct. 1, 2021– The federal government has taken dramatic action to get drug companies to restore 340B pricing for outpatient prescription drugs dispensed by community pharmacies to patients of 340B hospitals. On Sept. 22, the Health Resources & Services Administration (HRSA) sent letters to six drugmakers informing them that the agency is asking the Office of Inspector … [Read more...]
Boehringer Ingelheim Joins in the Attacks on 340B
July 12, 2021– The pharmaceutical giant Boehringer Ingelheim (BI), a manufacturer headquartered in Germany, is the latest company to announce it is cutting off discounts to safety-net hospitals participating in the 340B drug pricing program. If BI goes through with its threat on Aug. 1, it will become the seventh drug company to limit 340B discounts despite strong warnings by … [Read more...]